Cencora, Inc.: stock overview

CORNYSEHealthcare · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Price

$359.03

November 13, 2026Market cap $69.6B

DCF calculator

What Ploutos Investor adds for Cencora

Part of Ploutos Investor, €9.99 a month

See the plans

The full history: 17 fiscal years, from FY2009
The estimated fair value, with its range and its certainty
The full analysis, 18 a month
More questions to the chat on its filings
Excel with every year
An email when it reports, changes its dividend or an officer buys

Notes on these figures

The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

In short

Cencora had revenue of $333B over the last 12 months and net income of $2.6B, a net margin of 0.8%. Revenue grew by 11.1% a year on average over the last 5 years. At $359.03 the shares trade at a P/E of 26.5, against a median of 21.1 over the last 5 fiscal years. It has net debt of $8.9B. It pays a dividend yielding 0.69%.

From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 13, 2026.

Its SEC filings

Market cap: $69.6B; 194M shares
P/E: 26.5; Today26.5
Median21.1
Revenue, 12 months: $333B; +11.1% a year over 5 years
Net margin: 0.8%; FY2025: 0.5%, above 53% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

+10.7% a year over 2 years

FY2025Sep 30, 202510-K
Revenue$321B
FY2024Sep 30, 202410-K
Revenue$294B
FY2023Sep 30, 202310-K
Revenue$262B

Year	Revenue	Net income	EPS	Free cash flow	Dividend per share	Price
FY2025Sep 30, 202510-K	$321B	$1.6B	$7.96	$3.2B	$2.20	$312.53
FY2024Sep 30, 202410-K	$294B	$1.5B	$7.53	$3.0B	$2.04	$225.08
FY2023Sep 30, 202310-K	$262B	$1.7B	$8.53	$3.5B	$1.94	$179.97

Fiscal years in figures

COR's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $43.5B: $69.6B
Enterprise value: $78.6B
P/E 3-year median: 29.9: 26.5
EV / EBIT: 25.8
EV / Revenue: 0.2
P/B 3-year median: 67.3: 22.8
FCF yield 3-year median: 6.9%: 5.8%
Earnings yield 3-year median: 3.3%: 3.8%

Profitability

Gross margin: 4.0%
Operating margin: 0.9%
Net margin 3-year median: 0.5%: 0.8%
ROIC: 18.6%
ROIC, 5-year average: 30.5%
ROE: 110.8%

Growth

Revenue, yearly change: +9.3%
EPS, yearly change: +5.7%
FCF, yearly change: +7.0%
Revenue, average a year: +11.1%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash: $2.8B
Total debt: $11.7B
Net debt: $8.9B
Net debt / EBITDA: 2.2x
Interest cover: –
Current ratio: 0.93

Balance sheet of June 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 0.9%: 0.69%
Buybacks: 0.63%
Total returned: 1.32%
Shares, yearly change: +0.4%

Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 51).

Gross margin

3.6%

Above 24% of the 36 companies in its industry, and 4% of all.

Operating margin

0.8%

Above 46% of the 38 companies in its industry, and 37% of all.

Net margin

0.5%

Above 53% of the 39 companies in its industry, and 37% of all.

ROE

81.4%

Above 98% of the 26 companies in its industry, and 98% of all.

ROA

2.0%

Above 57% of the 38 companies in its industry, and 55% of all.

Revenue growth

9.3%

Above 81% of the 39 companies in its industry, and 60% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

Contracts with the US government

What the federal government committed in contracts to the company and its subsidiaries, by federal fiscal year (October to September).

$7.4B Fiscal year 2025

In federal fiscal year 2025 (October 2024 to September 2025) the US government committed $7.4B in contracts to the company and its subsidiaries. The year before it was $6.1B. That is about 2.3% of its revenue in the fiscal year to September 30, 2025 ($321B), though an amount committed is not revenue.

Fiscal year 2022Oct 2021 to Sep 2022

$2.0B

Fiscal year 2023Oct 2022 to Sep 2023

$4.4B

Fiscal year 2024Oct 2023 to Sep 2024

$6.1B

Fiscal year 2025Oct 2024 to Sep 2025

$7.4B

Fiscal year 2026Oct 2025 to Sep 2026

$6.6B

From USAspending.gov, the federal government's public spending records, as of November 1, 2026. An amount committed is not revenue of the same year: a contract running several years counts when it is signed, and the company is paid as it does the work. The company is matched through the parent company the government records it under, which adds up its subsidiaries. A subsidiary recorded under another parent can be missing.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC: Cencora, Inc.
CIK: 1140859
Exchange: NYSE
Industry (SIC): 5122 · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends: September 30
Latest annual report: September 30, 2025
Reporting currency: USD
Shares: 194M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

LLYEli Lilly and Company+0,00%

Compare with COR
JNJJohnson & Johnson+0,00%

Compare with COR
ABBVAbbVie+0,00%

Compare with COR
UNHUnitedHealth+0,00%

Compare with COR
MRKMerck & Company+0,00%

Compare with COR
AMGNAmgen+0,00%

Compare with COR
TMOThermo Fisher Scientific+0,00%

Compare with COR
ABTAbbott Laboratories+0,00%

Compare with COR

The Healthcare sector All companies

The full analysis

What do Cencora's filings show?

These are Cencora's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

A fair value range built from the filings
Earnings quality, debt and red flags
Insider and institutional moves
The case for and the case against

Questions about COR

Didn't find what you were looking for?

Ask us

What is COR's market cap?

Cencora, Inc.'s market cap is $69.6B, at a price of $359.03 on November 13, 2026 and 194M shares.

What is COR's P/E?

COR's P/E is 26.5, on earnings per share of $13.47 over the last 12 months. The median over the last 5 fiscal years was 21.1.

How much revenue does COR have?

Cencora had revenue of $333B over the last 12 months. Over the last 5 years it changed by +11.1% a year on average.

Does COR pay a dividend?

Yes. Cencora paid $2.46 per share over the last 12 months, a yield of 0.69% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Cencora, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.